Skip to main content

OGI

Stock
Health Care
Drug Manufacturers - Specialty & Generic

Performance overview

OGI Price
Price Chart

Forward-looking statistics

Beta
1.41
Risk
67.64%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

as part of canada’s marihuana for medical purposes regulations (mmpr), organigram (tsx-v:ogi) is atlantic canada's original licensed producer of medical marijuana. we are dedicated to consistently providing our clients with the highest quality, organically grown medicine and service. if you have questions or want to learn more, visit www.organigram.ca or give our client services team a call at 1-855-961-9420.

Company info

SectorHealth Care
IndustryDrug Manufacturers - Specialty & Generic
Employees678
Market cap$162.7M

Fundamentals

Enterprise value$155.3M
Revenue$142.7M
Revenue per employee
Profit margin8.70%
Debt to equity2.24

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)$0.13
Dividend per share
Revenue per share$1.72
Avg trading volume (30 day)$797K
Avg trading volume (10 day)$800K
Put-call ratio

Macro factor sensitivity

Growth-11.8
Credit+16.5
Liquidity+4.6
Inflation-17.2
Commodities-5.7
Interest Rates-1.5

Valuation

Dividend yield0.00%
PEG Ratio-20.43
Price to sales0.99
P/E Ratio-20.43
Enterprise Value to Revenue1.09
Price to book0.49

Upcoming events

Next earnings dayMay 12, 2025
Next dividend day
Ex. dividend day

News

Organigram Lights Up Q2 With 74% Sales Surge, Profitable Turn

Cannabis grower Organigram Holdings Inc  OGI reported second-quarter 2025 net sales of $45.7 million (approximately CA$65.6 million). That's up 74% year-over-year, beating the consensus of $42.28 million.

Benzinga (May 12, 2025)
OrganiGram (OGI) Reports Q2 Loss, Misses Revenue Estimates

OrganiGram (OGI) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to loss of $0.12 per share a year ago.

Zacks Investment Research (May 12, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free